3 results
Approved WMOCompleted
The primary objective of this study is to demonstrate the efficacy of the combination therapy of aliskiren (150 mg and 300 mg) and HCTZ 25 mg in hypertensive patients who do not show sufficient blood pressure response to a 4-week treatment of HCTZ…
Approved WMOCompleted
The primary objective of this study is to evaluate the safety and performance of the Permaseal device for left ventricular transapical access and closure and to gain data that will lead to CE-Mark approval for the Permaseal device.
Approved WMOCompleted
To investigate the safety, tolerability and pharmacokinetics after multiple daily doses of YTX-7739